Bernstein Sticks to Their Hold Rating for BeiGene (ONC)

In a report released today, Rebecca Liang from Bernstein maintained a Hold rating on BeiGene (ONC – Research Report), with a price target of $259.00. The company’s shares closed yesterday at $236.86.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Liang covers the Healthcare sector, focusing on stocks such as Innovent Biologics, BeiGene, and Sino Biopharmaceutical. According to TipRanks, Liang has an average return of 3.0% and a 66.67% success rate on recommended stocks.

BeiGene has an analyst consensus of Strong Buy, with a price target consensus of $325.59.

The company has a one-year high of $287.88 and a one-year low of $141.31. Currently, BeiGene has an average volume of 533.4K.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ONC in relation to earlier this year.